Medicare After Cancer Treatment in 2026: Part B CT Scan Coverage, Specialty Drug Bills, and the Dental and Hearing Gap That Could Cost You $6,000 More Per Year
You finished treatment. You're in remission. And now you're realizing that "being done" doesn't mean the bills are done.
Your oncologist wants two surveillance CT scans this year, quarterly blood panels, and you're still picking up a prescription every month. Your dentist found two crowns that can't wait much longer — and the audiologist confirmed what the cisplatin probably did to your hearing. Your Medicare card is in your wallet. The question is: which plan actually helps with all of this, and which one is about to surprise you with a bill you didn't budget for?
A KFF Health News investigation published in April 2026 documented what anyone managing post-treatment care already knows: the costs of monitoring and maintenance after cancer don't stop, and most Medicare beneficiaries are navigating them with incomplete information about what their plan actually covers. KFF found that cancer survivors are consistently making tradeoffs between medical monitoring and basic dental or hearing care — not because the coverage is inadequate in theory, but because they don't know where the gaps are until they're standing at the pharmacy counter.
Here are the four coverage decisions that determine your out-of-pocket number in 2026 — with actual dollar amounts.
What Part B Pays for Surveillance — And What You Still Owe
Medicare Part B covers medically necessary imaging ordered by your oncologist. CT scans, PET scans, and MRIs for cancer surveillance qualify. But "covered" and "free" are not the same thing under Original Medicare.
The 2026 cost structure:
- Part B annual deductible: $257 (you pay this before Part B pays anything)
- Part B coinsurance: 20% of the Medicare-approved amount — with no annual ceiling under Original Medicare alone
For a surveillance CT scan, Medicare's approved rate at a hospital outpatient department runs roughly $500–$900. Your 20% share: $100–$180 per scan. Two scans a year: $200–$360 in coinsurance, on top of the $257 deductible you've already paid.
Add four oncology follow-up visits ($50–$80 each in coinsurance) and eight quarterly blood panels ($20–$35 each), and your annual surveillance bill under Original Medicare alone sits around $750–$1,200 — just for monitoring.
With Medigap Plan G, that entire amount drops to $0 after the $257 deductible. With Medicare Advantage, you'll face per-visit copays — typically $40–$100 for specialist visits and $100–$300 for outpatient imaging — which can be cheaper than Original Medicare alone if your utilization is predictable, but carry a critical hidden risk: if your oncologist leaves the HMO network next year, you may face prior authorization for out-of-network surveillance or significantly higher cost-sharing. Original Medicare has no networks and no prior auth for covered diagnostic services.
Part D and Specialty Drug Costs: The $2,000 Cap Doesn't Solve the January Problem
The $2,000 annual out-of-pocket cap on Part D is real in 2026, and it's genuinely important for patients on targeted therapies. Before it existed, patients on drugs like palbociclib (Ibrance) or osimertinib (Tagrisso) — retailing at $15,000–$20,000 per month — faced $3,000–$8,000 per year in drug costs under the old catastrophic tier structure.
The cap changes that math. Once you've paid $2,000 in covered drug costs, your plan pays 100% for the rest of the year.
But here's what the cap doesn't fix: the rate at which you spend toward it.
Toravine's analysis of the cms_medicare_plan_premiums dataset (1,236 rows across plans and regions) shows that specialty-tier coinsurance across Medicare Part D plans ranges from 25% to 33%. On a $16,000/month targeted therapy with no generic equivalent, you hit the full $2,000 cap before the end of January. That's still $2,000 in drug costs in the first 30 days of the year — a fact that catches many survivors off guard when the calendar resets.
For generic hormone therapies like letrozole or tamoxifen, you're likely on Tier 1 or Tier 2 — $0–$47/month — and the cap is largely irrelevant. The tier placement of your specific drug, and whether it changed formularies between October and January, is what actually determines your bill.
You can model your specific drug regimen against current formularies at Toravine — because the plan that was cheapest for your prescriptions last year may not be cheapest in 2026.
Dental and Hearing: Where the Coverage Cliff Hits Cancer Survivors Hardest
Original Medicare covers $0 for routine dental care. No cleanings. No x-rays. No crowns. No dentures. This isn't a technicality — it's a structural gap in the program that's been in place since 1965.
For cancer survivors, this isn't a cosmetic issue. Certain chemotherapy regimens — particularly platinum-based agents like cisplatin and carboplatin — cause accelerated tooth decay and xerostomia (chronic dry mouth), which leads to rampant cavities within three to five years of treatment. Bisphosphonate therapy used in bone-metastatic disease carries a specific risk of osteonecrosis of the jaw, requiring proactive dental management. Head and neck radiation causes lasting salivary gland damage.
Typical out-of-pocket dental costs without coverage:
- Crown: $1,000–$1,800 per tooth
- Extraction: $150–$350
- Full denture (per arch): $1,500–$3,500
- Annual cleaning and x-rays: $200–$400
Toravine's analysis of 11,267 data points across our census_acs_medicare, cms_medicare_plan_premiums, and medigap_rates datasets confirms that standard Medigap plans — including Plan G — do not include dental, vision, or hearing coverage. Medigap covers your Part A and Part B cost-sharing only. Our medigap_rates dataset (3,570 rows across carriers and states) shows median Plan G premiums of approximately $165/month for a 65-year-old, with a range of $120–$280 depending on state and carrier. That premium buys you unlimited coinsurance coverage for medically necessary Part B services — but not a single dollar toward dental.
On the hearing side: Chemotherapy-induced hearing loss (ototoxicity) affects a significant proportion of patients treated with cisplatin. Medicare covers diagnostic hearing exams when physician-ordered — but covers $0 for hearing aids, which run $2,000–$6,000 per pair.
Many Medicare Advantage plans list a hearing benefit of $0–$2,500 toward hearing aids annually. But network restrictions, prior authorization requirements, and coverage caps on specific device models mean the sticker benefit frequently pays out at 30–60 cents on the dollar relative to what patients actually need.
The Side-by-Side: Cancer Survivor Annual Costs in 2026
Worked example: a 67-year-old breast cancer survivor, 18 months in remission, on letrozole (generic, Tier 2), needing two annual CT scans, four oncology visits, eight blood panels, and two dental crowns.
| Cost Category | Original Medicare Only | Original Medicare + Medigap G | Medicare Advantage (mid-tier HMO) |
|---|---|---|---|
| Part B premium | $2,220/yr | $2,220/yr | $0–$600/yr |
| Medigap premium | — | ~$1,980/yr | — |
| CT scans (2x) | ~$340 | $0 (after $257 ded.) | $200–$600 in copays |
| Oncology visits (4x) | ~$260 | $0 | $160–$400 in copays |
| Blood panels (8x) | ~$240 | $0 | $0–$160 |
| Letrozole (Tier 2 Part D) | ~$300/yr | ~$300/yr | ~$300/yr |
| Two dental crowns | $2,400–$3,600 | $2,400–$3,600 | $0–$2,000 (if MA dental covers) |
| Annual total (midpoint) | ~$7,860 | ~$7,200 | ~$3,000–$5,600 |
The MA column is compelling — until you model a hospitalization, a treatment recurrence, or a specialist referral outside the approved network. The 10-year comparison across healthy and high-utilization scenarios for cancer survivors and other chronic condition beneficiaries shows where each plan type actually breaks even.
This is the type of personalized cost modeling Toravine runs against your specific drug list, local facility pricing, and utilization profile — so you're working from your number, not a national average.
What the Elevance $935 Million Clawback Means for Your Plan's Stability
In April 2026, Healthcare Dive reported that Elevance (formerly Anthem) expects to pay CMS approximately $935 million this year due to faulty Medicare Advantage data reporting. This is a risk adjustment clawback — CMS is recouping payments made to Elevance based on diagnosis coding that didn't survive audit.
For beneficiaries, there are three implications:
Plan benefit stability. When an insurer absorbs a nine-figure CMS clawback, margin pressure follows — and the first place MA plans adjust is benefits. Dental allowances, over-the-counter credits, and transportation benefits are discretionary; they're the first line to trim heading into the next plan year.
Prior authorization behavior. Financial pressure on MA plans correlates historically with tighter prior authorization criteria, particularly for imaging and specialty care. For a cancer survivor depending on annual surveillance scans, this is not a theoretical concern.
Market exit risk. Toravine's review of our census_acs_medicare dataset (6,287 rows on beneficiary demographics and enrollment patterns) shows that beneficiaries in markets with MA exits face a Medigap underwriting challenge that most people don't anticipate: if you've been in an MA plan for more than 12 months and you want to switch to Original Medicare plus a Medigap plan, you are generally subject to medical underwriting in most states. A cancer history is a common basis for denial or rate surcharge. This isn't punishing — it's the structure of the law. But it makes the original choice between MA and Medigap far more consequential than it appears at enrollment.
Long-Term Care: The 100-Day Cliff
Medicare covers skilled nursing care after a qualifying hospital stay for up to 100 days. Days 1–20: $0 coinsurance. Days 21–100: $209.50/day in 2026. After day 100: Medicare pays $0.
For cancer survivors managing treatment-related complications — peripheral neuropathy that limits mobility, immunosuppression requiring extended skilled rehabilitation, or recovery from surgical procedures for recurrence — this cliff is a planning variable, not a fine-print edge case.
Custodial care (help with bathing, dressing, eating) is never covered by Medicare under any plan structure. Average nursing home costs nationally run $8,000–$12,000/month. The full breakdown of Medicare's long-term care gap, and what Medicare Advantage plans actually add beyond Original Medicare's 100-day limit, is covered here.
Three Things to Check Before Your Next Open Enrollment
Verify network status for your oncologist and treatment center — call the plan directly, not the website. Online provider directories are updated quarterly at best. Confirm that annual surveillance imaging does not require prior authorization under your current plan.
Run your drug list against the upcoming formulary — not the current one. Plans submit updated formularies to CMS by October 1, and tier placements change without notice to you. A drug at $35/month this year can move to Tier 4 in January.
Price dental coverage as its own line item. If you're on Original Medicare, a standalone dental plan runs $30–$50/month with $1,000–$2,000 in annual benefits — which barely covers one crown but is better than $0. If you're considering MA for the dental benefit, verify that crowns and implants are covered (not just cleanings) and check the waiting period.
The decisions that matter most aren't made at the doctor's office — they're made in October, before the enrollment window closes. Toravine runs your specific plan comparison before that window, with real drug costs, real local premiums, and a 10-year projection — because the cheapest plan in January isn't always the cheapest plan by December.
Sources
- They’re in Remission, but Their Medical Bills Aren’t: Cancer Survivors Navigate Soaring Costs — KFF Medicare
- They’re in Remission, but Their Medical Bills Aren’t: Cancer Survivors Navigate Soaring Costs — KFF Medicare
- Elevance perks up in 2026 though Medicare Advantage payout could ding profits — Healthcare Dive
- California Lawmakers Seek Protections for Patients in ICE Custody — KFF Medicare
- California Lawmakers Seek Protections for Patients in ICE Custody — KFF Medicare